Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
Cathie Wood is known for seeking out the most innovative companies, placing big bets on them early, and holding on for the long term. This strategy has helped her flagship Ark Innovation ETF climb more than 25% to outperform the S&P 500 so far this year. And even at times when the market and some of her favorite stocks slip, Wood buys -- reinforcing her commitment.
In recent weeks, the famous investor has been adding to her position in CRISPR Therapeutics (NASDAQ: CRSP) ahead of a very big event for the gene editing company. In December, the U.S. Food and Drug Administration (FDA) expects to issue a decision on what could become CRISPR's very first commercialized product. Should you join Wood and pile into this stock now? Let's find out.
First, let's talk a bit about CRISPR. The gene editing company's platform involves cutting DNA at a particular location so that a natural repair process can happen. The idea is to fix faulty genes responsible for certain diseases, and this means the technology could lead to functional cures. That's big news for patients -- and could result in significant revenue for CRISPR.
Source Fool.com
